GlassScriptPhysician profile
Jung H Lee
NPI 1942260849
$1,469.35
in general payments reported to CMS, 2019-2025
11 companies · $309 in 2025
The $309 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.86 · 2020: $14.13 · 2021: $175 · 2022: $31.89 · 2023: $356 · 2024: $537 · 2025: $309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,201.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novus Surgical Consultants | $399.05 | 2023-2025 | |
| Integra Lifesciences Corporation | $265.14 | 2021-2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Stryker Corporation | $257.89 | 2024-2025 | Infinity Adaptis, Phalinx |
| Kerecis Limited | $148.07 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Smith+Nephew, INC. | $114.92 | 2022-2023 | Grafix, Grafix Pl |
| Bone Support INC. | $89.68 | 2025 | Ceramentbone Void Filler, Cerament G |
| Kci USA, INC. | $86.50 | 2023 | Activ.A.C. Ion Progress, V.A.C. Veraflo Cleanse Choice |
| Merck Sharp & Dohme LLC | $46.86 | 2019 | |
| Zimmer Biomet Holdings, INC. | $26.81 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $20.30 | 2025 | Opsumit, Uptravi |
| Wright Medical Technology, INC. | $14.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jung Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.